CRL logo

CRL Stock Overview

Profile

Full Name:

Charles River Laboratories International, Inc.

Sector:

Healthcare

Industry:

Diagnostics & Research

Country:

United States

IPO:

June 23, 2000

Indexes:

S&P 500

Website:

http://www.criver.com

Description:

Charles River Laboratories International, Inc. is an American corporation that provides preclinical and clinical laboratory services to pharmaceutical, medical, and other industries, as well as government and academic organizations worldwide. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts, USA. Charles River Laboratories, Inc. provides a platform for conducting research on new drugs and treatment methods at any stage of development: specially bred rodents, over 150 laboratory and specialized disease strains, human cell materials, etc. The company also conducts safety testing of drugs, industrial chemicals, agrochemicals, consumer products, veterinary medicines, and medical devices through outsourcing.

Key Details

Price

$167.10

Market Cap

$8.55 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$4.05 B(-1.92% YoY)

Annual EPS

$0.20(-97.83% YoY)

PE Ratio

1114.00

Annual ROE

0.62%

Annual Debt To Equity

0.65

Beta

1.22

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 19, 2025

Recent annual earnings:

Feb 19, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 20, 25 JP Morgan
Neutral
Feb 20, 25 Barclays
Equal-Weight
Feb 20, 25 Baird
Neutral
Feb 18, 25 Barclays
Equal-Weight
Feb 5, 25 Morgan Stanley
Equal-Weight
Feb 3, 25 JP Morgan
Neutral
Jan 23, 25 Goldman Sachs
Buy
Jan 22, 25 William Blair
Market Perform
Jan 17, 25 UBS
Neutral
Jan 14, 25 William Blair
Outperform

Screeners with CRL included

Mid cap stocks
US stocks
High Piotroski score stocks
S&P 500 companies earnings calendar
Stocks with high beta
Stocks below SMA 200
Stocks recommended to hold
Best performing stocks last 5 years
S&P 500 companies
Stocks below analysts price target

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$167.10
CRL price is $167.10

Price All-time High

$458.30
CRL price is currently -63.54% below its historical high of $458.30

Price Analysts Target

$182.00
CRL price is currently -8.19% lower than the consensus analysts' forecast

Price Today Change

-1.65%
CRL price is down -1.65% today

Price YTD Change

-9.15%
CRL price is down -9.15% since January 1st

Price 3-Year Change

-43.58%
CRL price is down -43.58% over the past 3 years

Market cap

Market Cap

$8.55 B
CRL market capitalization is $8.55 billion

Market Cap 3-Year Change

-42.85%
CRL market capitalization is down -42.85% over the past 3 years

Market Cap All-time High

$23.13 B
CRL market capitalization is currently -63.05% below its historical high of $23.13 billion

Market Cap Sector Rank

91.14%
CRL market capitalization is higher than 91.14% of companies in Healthcare sector

Technical

Beta

1.22
CRL beta is 1.22

200-day SMA

$197.37
CRL price is currently -15.34% below its 200-day simple moving average

14-day RSI

51.85
CRL 14-day relative strength index is 51.85

30-day Relative Volume

1.79
CRL 30-day relative volume is 1.79

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$4.05 B
CRL annual revenue is $4.05 billion

Annual Revenue Analysts Estimate

$3.82 B
CRL annual revenue is currently +5.89% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

-1.92%
CRL annual revenue is down -1.92% year-on-year

Annual Revenue Sector Rank

90.85%
CRL annual revenue is higher than 90.85% of companies in Healthcare sector

Profit

Annual Gross Profit

$1.33 B
CRL annual gross profit is $1.33 billion

Annual Gross Margin

32.88%
CRL annual gross profit margin is 32.88%

Annual Operating Profit

$442.35 M
CRL annual operating income is $442.35 million

Annual Operating Margin

10.92%
CRL annual operating profit margin is 10.92%

Annual Net Income

$22.20 M
CRL annual net profit is $22.20 million

Annual Net Margin

0.55%
CRL annual net profit margin is 0.55%

EPS

Annual EPS

$0.20
CRL annual earnings per share is $0.20

Annual EPS Analysts Estimate

$9.43
CRL annual earnings per share is currently -97.88% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-97.83%
CRL annual earnings per share is down -97.83% year-on-year

Annual EPS Sector Rank

85.8%
CRL annual earnings per share is higher than 85.8% of companies in Healthcare sector

ROA & ROE

Annual ROA

0.28%
CRL annual return on assets is 0.28%

Annual ROE

0.62%
CRL annual return on equity is 0.62%

EBIT & EBITDA

Annual EBIT

$219.40 M
CRL annual earnings before interest & taxes is $219.40 million

Annual EBITDA

$581.14 M
CRL annual EBITDA is $581.14 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

1114.00
CRL price to earnings ratio is 1114.00

PE Ratio Sector Rank

100%
CRL price to earnings ratio is higher than 100% of companies in Healthcare sector

PB Ratio

PB Ratio

2.47
CRL price to book ratio is 2.47

PB Ratio Sector Rank

64.75%
CRL price to book ratio is higher than 64.75% of companies in Healthcare sector

PS Ratio

PS Ratio

2.11
CRL price to sales ratio is 2.11

PS Ratio Sector Rank

40.83%
CRL price to sales ratio is higher than 40.83% of companies in Healthcare sector

Enterprise value

Enterprise Value

$11.08 B
CRL enterprise value is $11.08 billion

Enterprise Value Sector Rank

92.95%
CRL enterprise value is higher than 92.95% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

19.06
CRL EV/EBITDA is 19.06

EV/EBITDA Sector Rank

90.41%
CRL EV/EBITDA is higher than 90.41% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

1.41
CRL annual current ratio is 1.41

Annual Quick Ratio

1.13
CRL annual quick ratio is 1.13

Leverage

Annual Debt To Equity

0.65
CRL annual debt to equity ratio is 0.65

Annual Interest Coverage Ratio

1.74
CRL annual interest coverage ratio is 1.74

Risk & Stability

Piotroski F-Score

6
CRL piotroski f-score is 6

Altman Z-Score

2.31
CRL altman z-score is 2.31

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$7.53 B
CRL annual total assets is $7.53 billion

Annual Non Current Assets

$6.13 B
CRL annual long term assets is $6.13 billion

Annual Current Assets

$1.40 B
CRL annual total current assets is $1.40 billion

Annual Cash & Cash Equivalents

$194.61 M
CRL annual cash & cash equivalents is $194.61 million

Equity

Annual Book Value

$3.46 B
CRL annual book value is $3.46 billion

Annual Working Capital

$408.97 M
CRL annual working capital is $408.97 million

Liabilities

Annual Total Liabilities

$4.02 B
CRL annual total liabilities is $4.02 billion

Annual Total Long Term Liabilities

$3.03 B
CRL annual total long term liabilities is $3.03 billion

Annual Current Liabilities

$994.10 M
CRL annual total current liabilities is $994.10 million

Annual Accounts Payable

$140.34 M
CRL annual accounts payable is $140.34 million

Debt

Annual Total Debt

$2.72 B
CRL annual total debt is $2.72 billion

Annual Total Debt 1-Year Change

-11.17%
CRL annual total debt is down -11.17% year-on-year

Annual Long Term Debt

$2.72 B
CRL annual long term debt is $2.72 billion

Annual Short Term Debt

-
CRL annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$3.61 B
CRL annual total expenses is $3.61 billion

Annual Operating Expenses

$889.47 M
CRL annual total operating expenses is $889.47 million

Annual Cost Of Goods Sold

$2.72 B
CRL annual cost of goods sold is $2.72 billion

Annual SGA

$751.00 M
CRL annual SGA is $751.00 million

Annual D&A

$361.74 M
CRL annual depreciation & amortization is $361.74 million

Annual Interest Expense

$126.29 M
CRL annual interest expense is $126.29 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$734.58 M
CRL annual cash flow from operations is $734.58 million

Annual CFO 1-Year Change

+7.41%
CRL annual cash flow from operations is up +7.41% year-on-year

Annual CFI

-$245.09 M
CRL annual cash flow from investing activities is -$245.09 million

Annual CFI 1-Year Change

+56.48%
CRL annual cash flow from investing activities is up +56.48% year-on-year

Annual CFF

-$550.93 M
CRL annual cash flow from financing activities is -$550.93 million

Annual CFF 1-Year Change

-544.2%
CRL annual cash flow from financing activities is down -544.2% year-on-year

Free CashFlow

Annual FCF

$501.61 M
CRL annual free cash flow is $501.61 million

Annual FCF 1-Year Change

+37.29%
CRL annual free cash flow is up +37.29% year-on-year

CAPEX

Annual CAPEX

$232.97 M
CRL annual capital expenditures is $232.97 million

Annual CAPEX 1-Year Change

-26.86%
CRL annual capital expenditures is down -26.86% year-on-year

Institutional Ownership

Similar stocks

QGEN logo
Qiagen NV (QGEN)
JAZZ logo
Jazz Pharmaceuticals (JAZZ)
CHE logo
Chemed (CHE)
TFX logo
Teleflex Incorporated (TFX)
RGEN logo
Repligen (RGEN)
ASND logo
Ascendis Pharma A/S (ASND)
TEM logo
Tempus AI (TEM)
ENSG logo
Ensign (ENSG)
EXAS logo
Exact Sciences (EXAS)

FAQ

  • What is the ticker symbol for Charles River Laboratories International?
  • Does Charles River Laboratories International pay dividends?
  • What sector is Charles River Laboratories International in?
  • What industry is Charles River Laboratories International in?
  • What country is Charles River Laboratories International based in?
  • When did Charles River Laboratories International go public?
  • Is Charles River Laboratories International in the S&P 500?
  • Is Charles River Laboratories International in the NASDAQ 100?
  • Is Charles River Laboratories International in the Dow Jones?
  • When was Charles River Laboratories International's last earnings report?
  • When does Charles River Laboratories International report earnings?
  • Should I buy Charles River Laboratories International stock now?

What is the ticker symbol for Charles River Laboratories International?

The ticker symbol for Charles River Laboratories International is NYSE:CRL

Does Charles River Laboratories International pay dividends?

No, Charles River Laboratories International does not pay dividends

What sector is Charles River Laboratories International in?

Charles River Laboratories International is in the Healthcare sector

What industry is Charles River Laboratories International in?

Charles River Laboratories International is in the Diagnostics & Research industry

What country is Charles River Laboratories International based in?

Charles River Laboratories International is headquartered in United States

When did Charles River Laboratories International go public?

Charles River Laboratories International's initial public offering (IPO) was on June 23, 2000

Is Charles River Laboratories International in the S&P 500?

Yes, Charles River Laboratories International is included in the S&P 500 index

Is Charles River Laboratories International in the NASDAQ 100?

No, Charles River Laboratories International is not included in the NASDAQ 100 index

Is Charles River Laboratories International in the Dow Jones?

No, Charles River Laboratories International is not included in the Dow Jones index

When was Charles River Laboratories International's last earnings report?

Charles River Laboratories International's most recent earnings report was on Feb 19, 2025

When does Charles River Laboratories International report earnings?

The next expected earnings date for Charles River Laboratories International is May 9, 2025

Should I buy Charles River Laboratories International stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions